Executive summary
The UK regulates peptides under the Human Medicines Regulations 2012 (SI 2012/1916) and the Medicines Act 1968. The MHRA is the standalone regulator post-Brexit. Peptide medicines require a UK Marketing Authorisation (UKMA). Compounding is governed by Section 10 of the Medicines Act 1968. The MHRA actively investigates unlicensed peptide clinics and online vendors.
Authorities and legal categories
MHRA: marketing authorisation, borderlines, enforcement, specials, import licensing, pharmacovigilance.
GPhC: regulates pharmacy professionals and premises in Great Britain.
CAP (Committee of Advertising Practice) / ASA: advertising standards for non-broadcast marketing.
Key instruments:
Human Medicines Regulations 2012 (SI 2012/1916).
Medicines Act 1968, Section 10 — pharmacy compounding exemption.
SI 2013/1855 — FMD initial transposition.
SI 2019/62 — FMD safety features (disapplied post-Brexit for GB and NI).
Medicines and Medical Devices Act 2021 — post-Brexit framework.
Approved medicines
Licensed peptide-class medicines in the UK include semaglutide (Ozempic, Wegovy, Rybelsus), tirzepatide (Mounjaro), liraglutide (Victoza, Saxenda), insulin analogues, teriparatide (Forsteo), leuprorelin (Prostap), goserelin (Zoladex), octreotide (Sandostatin), desmopressin, salmon calcitonin, and nafarelin (Synarel). All are prescription-only medicines (POM).
Source: MHRA marketing authorisations, https://www.gov.uk/government/publications/marketing-authorisations-granted-in-2026
Investigational use
Clinical trials in the UK operate under a separate regime from the EU CT Regulation. The MHRA can authorise trials through the national procedure. ILAP (Innovative Licensing and Access Pathway) offers accelerated engagement for innovative peptide therapeutics.
Compounding/manufacturing
Section 10 of the Medicines Act 1968 exempts pharmacists from requiring a manufacturer's licence when:
Preparing or dispensing in a registered pharmacy pursuant to a prescription;
Under the supervision of a pharmacist;
For an identified patient.
The exemption does not permit stockpiling or wholesale-like supply.
Specials (Regulation 167 of HMR 2012, also IR 2012/1916): An unlicensed medicinal product can be supplied if all conditions are met:
Unsolicited order;
Manufactured to a prescriber's specification;
For a patient under that prescriber's direct responsibility;
No suitable licensed alternative;
Made or imported by a holder of a Manufacturer's "Specials" Licence (MSL).
Import, sale, advertising, and online supply
Import: requires a Wholesale Distribution Licence (WDA(H)) for imports from approved countries, or an MIA/MSL from non-approved countries. A Notification of Intent to Import must be submitted to MHRA for unlicensed products; 28-day assessment period.
Personal import exemption: no formal personal-use defence exists in UK law for unapproved medicines.
Online: Part 14 of HMR 2012 prohibits POM advertising to the public. The joint CAP/MHRA/GPhC enforcement notice (September 2025) specifically addresses advertising of prescription-only weight-management medicines (GLP-1 agonists).
GPhC guidance (updated February 2025): registered pharmacies offering distance-selling services must verify identity, ensure two-way communication before prescribing high-risk medicines, and not rely solely on online questionnaires.
Research-use-only products
MHRA Borderlines Head Lynda Scammell (April 2026): "We disregard claims that products are for 'research purposes' if it is clear that such claims are being used as an attempt to avoid medicines regulations." The MHRA looks at promotional material, claims, dosing guidance, and FAQ content — not just label wording. Enforcement against "research peptide" vendors is active.
Sport/anti-doping overlay
UK Anti-Doping (UKAD) enforces WADA rules for UK athletes.
Enforcement examples and uncertainty
April 2026: MHRA announced investigation into peptide clinics making unverified medicinal claims.
The MHRA has taken enforcement action against websites selling melanotan II and other unlicensed peptides.
Post-Windsor Framework (January 2025): all UK MAs are now UK-wide; EU FMD safety features fully disapplied; separate UK pharmacovigilance regime.
GPhC fitness-to-practise (January 2026): warning issued to a pharmacist who imported unlicensed POMs from China.
Practical interpretation limits
This is general regulatory research, not legal advice. Classification can turn on composition, claims, intended use, route, supplier role, and facts not captured by a product name.
Primary sources
Human Medicines Regulations 2012 (SI 2012/1916). https://www.legislation.gov.uk/uksi/2012/1916/contents
Medicines Act 1968, Section 10. https://www.legislation.gov.uk/ukpga/1968/67/section/10
ILAP Guidance. https://www.gov.uk/government/publications/marketing-authorisations-granted-in-2026
MHRA Import Guidance. https://www.gov.uk/guidance/import-a-human-medicine
GPhC Distance-Selling Guidance (Feb 2025). https://assets.pharmacyregulation.org/files/2025-02/gphc-guidance-registered-pharmacies-providing-pharmacy-services-distance-february-2025.pdf
GPhC Weight Management Review (Apr 2026). https://assets.pharmacyregulation.org/files/2026-04/Weight-management-medicines-and-services-a-review-of-GPhC-inspections-and-concerns-April-2026.pdf
MHRA on Peptide Clinics (Apr 2026). https://www.theguardian.com/society/2026/apr/04/medicines-watchdog-to-investigate-uk-peptide-clinics-over-health-claims